A5059793455- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Neurological Disease Mechanisms and Treatments
- Advanced Neuroimaging Techniques and Applications
- Neuroinflammation and Neurodegeneration Mechanisms
- Medical Imaging Techniques and Applications
- Health Systems, Economic Evaluations, Quality of Life
- Cancer-related cognitive impairment studies
- Cerebrovascular and Carotid Artery Diseases
- S100 Proteins and Annexins
- Health, Environment, Cognitive Aging
- Neuroscience and Neuropharmacology Research
- Cerebrospinal fluid and hydrocephalus
- Bioinformatics and Genomic Networks
- Traumatic Brain Injury and Neurovascular Disturbances
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Intensive Care Unit Cognitive Disorders
- Diet and metabolism studies
- Blood Pressure and Hypertension Studies
- Epilepsy research and treatment
- Neurological Disorders and Treatments
- Statistical Methods in Clinical Trials
- COVID-19 and Mental Health
- Memory and Neural Mechanisms
The Memory Clinic
2022-2025
Lund University
2022-2025
Barcelonaβeta Brain Research Center
2018-2024
Pasqual Maragall Foundation
2019-2024
Amsterdam Neuroscience
2024
Vrije Universiteit Amsterdam
2022-2024
Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable
2020-2024
Hospital Del Mar
2019-2023
Hospital del Mar Research Institute
2019-2023
Municipal Institute for Medical Research
2019-2023
Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that increases in the cerebrospinal fluid (CSF) and blood individuals with Alzheimer disease (AD). However, it not known whether there are differences GFAP levels across entire AD continuum its performance similar to CSF GFAP.To evaluate plasma throughout continuum, from preclinical dementia, compared GFAP.This observational, cross-sectional study collected data July 29, 2014, January 31, 2020, 3 centers. The...
Article10 November 2020Open Access Transparent process Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of preclinical Alzheimer's continuum when only subtle changes Aβ pathology are detected Marc Suárez-Calvet orcid.org/0000-0002-2993-569X Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain IMIM (Hospital del Mar Medical Institute), Servei de Neurologia, Hospital Mar, Centro Investigación Biomédica en Red sFragilidad...
Abstract Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s disease are needed to facilitate the initial screening process of participants disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathology, but a comprehensive comparison with other putative blood is lacking. In ALFA+ cohort, all tested plasma (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed...
Abstract Introduction The biological pathways involved in the preclinical stage of Alzheimer's continuum are not well understood. Methods We used NeuroToolKit and Elecsys ® immunoassays to measure cerebrospinal fluid (CSF) amyloid‐β (Aβ)42, Aβ40, phosphorylated tau (p‐tau), total (t‐tau), neurofilament light (NfL), neurogranin, sTREM2, YKL40, GFAP, IL6, S100, α‐synuclein cognitively unimpaired participants ALFA+ study, many within . Results CSF t‐tau, p‐tau, neurogranin increase throughout...
With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying patients who could benefit from these treatments becomes critical. In this study, we evaluated whether a precise blood test perform as well established cerebrospinal fluid (CSF) tests in detecting amyloid-β (Aβ) plaques and tau tangles. Plasma %p-tau217 (ratio phosporylated-tau217 to non-phosphorylated tau) was analyzed by mass spectrometry Swedish BioFINDER-2 cohort (n = 1,422) US Charles F. Joanne...
Importance Alzheimer disease (AD) pathology starts with a prolonged phase of β-amyloid (Aβ) accumulation without symptoms. The duration this differs greatly among individuals. While has high relevance for clinical trial designs, it is currently unclear how to best predict the onset progression. Objective To evaluate combinations different plasma biomarkers predicting cognitive decline in Aβ-positive cognitively unimpaired (CU) Design, Setting, and Participants This prospective...
Abstract Aggregated insoluble tau is one of two defining features Alzheimer’s disease. Because clinical symptoms are strongly correlated with aggregates, drug development and diagnosis need cost-effective accessible specific fluid biomarkers aggregates; however, recent studies suggest that the currently available cannot specifically track aggregates. We show microtubule-binding region (MTBR) containing residue 243 (MTBR-tau243) a new cerebrospinal (CSF) biomarker for aggregates compared it...
Several promising plasma biomarkers for Alzheimer's disease have been recently developed, but their neuropathological correlates not yet fully determined. To investigate and compare independent associations between multiple (p-tau181, p-tau217, p-tau231, Aβ42/40, GFAP, NfL) neuropathologic measures of amyloid tau, we included 105 participants from the Arizona Study Aging Neurodegenerative Disorders (AZSAND) with antemortem samples a postmortem exam, 48 whom had longitudinal p-tau217...
Cerebrospinal fluid (CSF) amyloid-β peptide (Aβ)42/Aβ40 and the concentration of tau phosphorylated at site 181 (p-tau181) are well-established biomarkers Alzheimer's disease (AD). The present study used mass spectrometry to measure concentrations nine five nonphosphorylated species phosphorylation occupancies (percentage phosphorylated/nonphosphorylated) ten sites. In we show that, in 750 individuals with a median age 71.2 years, CSF pT217/T217 predicted presence brain amyloid by positron...
Abstract Biological staging of individuals with Alzheimer’s disease (AD) may improve diagnostic and prognostic workup dementia in clinical practice the design trials. In this study, we used Subtype Stage Inference (SuStaIn) algorithm to establish a robust biological model for AD using cerebrospinal fluid (CSF) biomarkers. Our analysis involved 426 participants from BioFINDER-2 was validated 222 Knight Alzheimer Disease Research Center cohort. SuStaIn identified singular biomarker sequence...
Abstract Background Novel phosphorylated-tau (p-tau) blood biomarkers (e.g., p-tau181, p-tau217 or p-tau231), are highly specific for Alzheimer’s disease (AD), and can track amyloid-β (Aβ) tau pathology. However, because these strongly associated with the emergence of Aβ pathology, it is difficult to determine contribution insoluble aggregates plasma p-tau signal in blood. Therefore, there remains a need biomarker capable specifically tracking accumulation brain. Methods NTA novel...
Importance Phase 3 trials of successful antiamyloid therapies in Alzheimer disease (AD) have demonstrated improved clinical efficacy people with less severe disease. Plasma biomarkers will be essential for efficient screening participants future primary prevention testing cognitively unimpaired (CU) individuals initially low brain β-amyloid (Aβ) levels who are at high risk accumulating Aβ. Objective To investigate if combining plasma could useful predicting subsequent development Aβ...
Abstract Background Antibody-based immunoassays have enabled quantification of very low concentrations phosphorylated tau (p-tau) protein forms in cerebrospinal fluid (CSF), aiding the diagnosis AD. Mass spectrometry enables absolute multiple p-tau variants within a single run. The goal this study was to compare performance mass assessments 181 , 217 and 231 with established immunoassay techniques. Methods We measured CSF from 173 participants TRIAD cohort 394 BioFINDER-2 using both methods....
Abstract Proteomics can shed light on the dynamic and multifaceted alterations in neurodegenerative disorders like Alzheimer’s disease (AD). Combining radioligands measuring β-amyloid (Aβ) plaques tau tangles with cerebrospinal fluid proteomics, we uncover molecular events mirroring different stages of AD pathology living humans. We found 127 differentially abundant proteins (DAPs) across spectrum. The strongest Aβ-related were mainly expressed glial cells included SMOC1 ITGAM. A dozen...
Abstract The Aβ 42 /Aβ 40 ratio in the cerebrospinal fluid (CSF) and concentrations of neurofilament light (NfL) total tau (t-tau) are changed early stages Alzheimer’s disease (AD) 1 , but their neurobiological correlates not entirely understood. Here, we used 5xFAD transgenic mice to investigate associations between these CSF biomarkers measures cerebral Aβ, including ratios plaques, insoluble fibrillar deposits soluble protofibrils. A high protofibrils was strongest independent predictor...
Abstract The APOE4 allele is the strongest genetic risk factor for sporadic Alzheimer’s disease (AD). While strongly associated with amyloid-beta (Aβ), its relationship tau accumulation less understood. Studies evaluating role of on showed conflicting results, particularly regarding independence these associations from Aβ load. In this study, we examined three independent longitudinal cohorts (BioFINDER-1, BioFINDER-2 and WRAP) in which participants had cross-sectional measures tangles...
The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values this continuous measurement enable the consistent operationalization decision-making for multicentre research studies and clinical trials. In study, we aimed at deriving reference thresholds that maximize agreement against core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers in two large independent cohorts.
Abstract Background Mounting evidence links poor sleep quality with a higher risk of late-life dementia. However, the structural and cognitive correlates insomnia are still not well understood. The study aims were to characterize performance brain pattern cognitively unimpaired adults at increased for Alzheimer’s disease (AD) insomnia. Methods This cross-sectional included 1683 middle/late-middle-aged from ALFA (ALzheimer FAmilies) who underwent neuropsychological assessment, T1-weighted...
<h3>Objective</h3> To develop and evaluate a model for staging cortical amyloid deposition using PET with high generalizability. <h3>Methods</h3> Three thousand twenty-seven individuals (1,763 cognitively unimpaired [CU], 658 impaired, 467 Alzheimer disease [AD] dementia, 111 non-AD 28 missing diagnosis) from 6 cohorts (European Medical Information Framework AD, Alzheimer9s Family, Biomarkers in Daily Practice, Amsterdam Dementia Cohort, Open Access Series of Imaging Studies [OASIS]-3,...
Air quality contributes to incidence of Alzheimer’s disease (AD) although the underlying neurobiological mechanisms are unclear. This study was aimed examine association between air pollution and concentrations cerebrospinal fluid (CSF) AD biomarkers amyloid-β (Aβ) deposition. Participants methods The sample included 156 cognitively unimpaired adults aged 57 years (61 at assessment) with increased risk from ALFA + Study. We examined CSF levels Aβ42, Aβ40, p-Tau, t-Tau, neurofilament light...
β-amyloid (Aβ) staging models assume a single spatial-temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation subtypes by applying the data-driven Subtype and Stage Inference (SuStaIn) model to amyloid-PET data.Amyloid-PET data 3,010 participants were pooled from 6 cohorts (ALFA+, EMIF-AD, ABIDE, OASIS, ADNI). Standardized uptake value ratios calculated 17 regions. applied SuStaIn algorithm identify consistent in dataset based on cross-validation information...
Our objective was determining the optimal combinations of cerebrospinal fluid (CSF) biomarkers for predicting disease progression in Alzheimer's (AD) and other neurodegenerative diseases.